Nancy Peacock, MD
Medical Oncology · Nashville, TNNPI 1194751354
Payments from drug & device makers
Across 105 payments — averaging $38.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Puma Biotechnology, Inc.$1K
- Merck$490
- Pacira Pharmaceuticals Incorporated$483
- Novartis$372
- Genentech USA, Inc.$182
- AstraZeneca$164
- plus $1K from 23 others
Across 2 payments — averaging $413.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$827
What the payments were for
- Consulting fees$1,00025%
- Food & beverage$2,86572%
- Education$1293%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Puma Biotechnology, Inc. | 2 | $1,016 |
| Merck | 22 | $490 |
| Pacira Pharmaceuticals Incorporated | 1 | $483 |
| Novartis | 16 | $372 |
| Genentech USA, Inc. | 3 | $182 |
| AstraZeneca | 3 | $164 |
| AbbVie | 6 | $139 |
| Johnson & Johnson | 5 | $111 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| Daiichi Sankyo Inc. | 4 | $98 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $97 |
| Bristol Myers Squibb | 4 | $85 |
| Astellas Pharma US Inc | 5 | $84 |
| Pfizer | 4 | $79 |
| Eisai Inc. | 3 | $70 |
| Seagen Inc. | 1 | $60 |
| Bayer | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Beigene USA, Inc. | 2 | $37 |
| Gilead(2 entities) | 2 | $32 |
| GSK | 1 | $28 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Incyte Corporation | 2 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $20 |
| Biocompatibles, Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $18 |
| Accord Healthcare, Inc. | 1 | $17 |
| Exelixis Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,994 in reported general payments places this provider in the 30th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 66 | $1,012,504 |
| RevlimidLenalidomide | 43 | $677,864 |
| CalquenceAcalabrutinib Maleate | 24 | $326,197 |
| CabometyxCabozantinib S-Malate | 11 | $286,385 |
| TasignaNilotinib Hcl | 24 | $262,857 |
| ImbruvicaIbrutinib | 12 | $262,774 |
| GilotrifAfatinib Dimaleate | 23 | $251,005 |
| JakafiRuxolitinib Phosphate | 16 | $213,162 |
| AlecensaAlectinib Hcl | 12 | $209,119 |
| KisqaliRibociclib Succinate | 12 | $128,210 |
| BrukinsaZanubrutinib | 12 | $84,972 |
| EliquisApixaban | 16 | $10,344 |
| Anastrozole | 233 | $4,637 |
| Letrozole | 119 | $2,683 |
| Exemestane | 25 | $2,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $79 | $1,022,84782 claims |
| Bristol Myers SquibbRevlimid | $85 | $677,86443 claims |
| NovartisTasigna, Kisqali | $372 | $391,06736 claims |
| AstraZenecaCalquence | $164 | $326,19724 claims |
| Exelixis Inc.Cabometyx | $13 | $286,38511 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $97 | $262,77412 claims |
| Incyte CorporationJakafi | $25 | $213,16216 claims |
| Genentech USA, Inc.Alecensa | $182 | $209,11912 claims |
| Beigene USA, Inc.Brukinsa | $37 | $84,97212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 101 medical oncology providers in Tennessee.
Other medical oncology in Nashville
- Melissa JohnsonNashville$46M
- David SpigelNashville$29.7M
- Howard BurrisNashville$12.2M
- Ingrid MayerNashville$6.3M
- Jennifer ChoeNashville$4.1M
- Cathy EngNashville$3.8M
- Jordan BerlinNashville$3.7M
- Kristen CiomborNashville$3.2M
- Vandana AbramsonNashville$3M
- Leora HornNashville$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.